Massive Real-World study digs into TMS effectiveness for depression and OCD

NCT ID NCT06917339

Recruiting now Knowledge-focused Sponsor: Neuronetics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at medical records from over 150,000 people who received NeuroStar TMS (a non-invasive brain stimulation treatment) for depression, OCD, or anxiety. Researchers want to find out which patient traits and treatment settings lead to the best results. No new treatments are given—the goal is to learn from existing data to improve future care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANXIETY DEPRESSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Depression depressive disorder mixed anxiety and depressive disorder obsessive-compulsive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANXIETY DEPRESSION DEPRESSION OBSESSIVE-COMPULSIVE DISORDER

Contacts and locations

Locations

Neuronetics
RECRUITING

Malvern, Pennsylvania, 19355, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.